In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma

British Journal of Cancer

Volumn 85, Issue 5, 2001, Pages 741-746

  Kikuchi, A ^a,b   Nieda, M ^a   Schmidt, C ^b   Koezuka, Y ^c   Ishihara, S ^d   Ishikawa, Y ^a   Tadokoro, K ^a   Durrant, S ^e   Boyd, A ^b   Juji, T ^a   Nicol, A ^b,e  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c KIRIN BREWERY CO LTD   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

GalCer; Anti tumour activity; IFN ; Melanoma; V 24+NKT cells

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DENDRITIC CELL; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPERNATANT;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; CELL DIVISION; GALACTOSYLCERAMIDES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 0035446146     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1973     Document Type: Article

References (18)

1. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells
2. Oligosaccharide ligands for NKRPI protein activate NK cells and cytotoxicity
3. Immunization with alpha-galactosylceramide polarizes CDI-reactive NK T cells towards Th2 cytokine synthesis
4. The CDI system
5. Diverse CDId-restricted reactivity patterns of human T cells bearing 'invariant' AV24BV11 TCR
6. Requirement for Valphal4 NKT cells in IL-12-mediated rejection of tumours
7. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8-T cells
8. Bacillus Calmette-Guerin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferongamma, which inhibits B 16F10 melanoma cell growth in vitro
9. Cytokine therapy: Lessons learned and future challenges
10. Natural killer-like nonspecific tumour cell lysis mediated by specific ligand-activated Valphal4 NKT cells
11. CDId-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides
12. Antitumour cytotoxicity mediated by ligand-activated human V alpha24 NKT cells
13. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
14. KRN7000, a novel immunomodulator, and its antitumour activities
15. Human invariant Vα24+NKT cells activated by α-GalactosylCeramide (KRN7000) have cytotoxic antitumour activity through mechanisms distinct from T cells and NK cells
16. Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CDId-restricted and Valpha24TCR-mediated manner
17. Analysis of human Va24+CD4+NKT cells activated by α-glycosylceramide-pulsed monocyte-derived dendritic cells
18. IL-12 directly up-regulates the expression of HLA class I. HLA class II and ICAM-I on human melanoma cells: A mechanism for its antitumour activity?